2011
DOI: 10.1111/j.1468-1331.2011.03559.x
|View full text |Cite
|
Sign up to set email alerts
|

Five‐year experience with incobotulinumtoxinA (Xeomin®): the first botulinum toxin drug free of complexing proteins

Abstract: In 2005, incobotulinumtoxinA (Xeomin(®) ), a new botulinum toxin (BT) type A drug without complexing proteins (CPs), became available. This paper reviews the specific features of Xeomin(®) and the experience gathered with it during the last 5 years. Compared with conventional BT drugs, Xeomin(®) 's extended shelf live and its simplified temperature restrictions indicate that CPs are not necessary for BT drug stability. Its reduced molecular size does not translate into diffusion differences, and its potency l… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
38
0
4

Year Published

2014
2014
2022
2022

Publication Types

Select...
4
3
1

Relationship

1
7

Authors

Journals

citations
Cited by 65 publications
(44 citation statements)
references
References 32 publications
2
38
0
4
Order By: Relevance
“…In 1998, a new batch of onabotulinumtoxinA was prepared with a lower protein load and there have been reports of decreased resistance [40]. As mentioned above, incobotulinumtoxinA is free of accessory proteins and contains less inactive toxin, with speculation that it is less likely to cause neutralizing antibodies, though evidence is lacking [29]. Assays to detect neutralizing antibodies are not readily available and not routinely used in clinical practice.…”
Section: Botulinum Toxinmentioning
confidence: 99%
See 1 more Smart Citation
“…In 1998, a new batch of onabotulinumtoxinA was prepared with a lower protein load and there have been reports of decreased resistance [40]. As mentioned above, incobotulinumtoxinA is free of accessory proteins and contains less inactive toxin, with speculation that it is less likely to cause neutralizing antibodies, though evidence is lacking [29]. Assays to detect neutralizing antibodies are not readily available and not routinely used in clinical practice.…”
Section: Botulinum Toxinmentioning
confidence: 99%
“…All the above-mentioned formulations need to be stored in a cool environment, except for incobotulinumtoxinA, which is stable at room temperature. IncobotulinumtoxinA is free of accessory proteins and contains less inactive toxin, but evidence is still lacking whether it is less likely to cause neutralizing antibodies [29]. RimabotulinumtoxinB may have greater tendency for autonomic side effects such as dry mouth and constipation [30].…”
Section: Botulinum Toxinmentioning
confidence: 99%
“…Vials contained 100 mouse lD50 units of botulinum toxin type A (corresponding to 0.44 ng total clostridial protein content), 1.0 mg human serum albumin, and 4.7 mg sodium sucrose (Dressler, 2012). lyophilized botulinum toxin A complex (0.44 ng) was diluted with culture medium containing the glutamate-receptor antagonists AP5 (20 µM) and CNQX (15 µM).…”
Section: Chemicalsmentioning
confidence: 99%
“…Medicinal products containing botulinum toxin A are in current use for treating several diseases including dystonia, migraine, hyperhydrosis, blepharospasm and torticollis (Dressler, 2012;Schiavo et al, 2000). According to legal regulations, each botulinum toxin batch must undergo potency testing (Adler et al, 2010).…”
Section: Introductionmentioning
confidence: 99%
“…Local injections of botulinum toxin (BT) are effective and well tolerated in the symptomatic treatment of focal dystonias, including cervical dystonia (CD) [1][2][3]. The therapeutic effect of BT in CD follows a typical time course [4].…”
Section: Introductionmentioning
confidence: 99%